Three amino acids from the tail of a pigment hormone, with a real anti-inflammatory signal in cells and mice, no human study of any kind, and an advisory committee vote in its favour that the FDA's own scientists opposed.

Summary

KPV is the tripeptide lysine-proline-valine, residues 11 to 13 of alpha-melanocyte-stimulating hormone. It keeps the parent hormone's anti-inflammatory activity and loses its pigment-inducing activity.1
It does not act through the melanocortin receptors that mediate alpha-MSH's effects. Its molecular target is unknown; in gut cells it is carried in by the peptide transporter PepT1 and inhibits NF-κB signalling.2 3
In mice, KPV in drinking water reduced chemically induced colitis, and injected KPV reduced skin inflammation. Those are the studies behind every claim made for it.2 4
No human study of KPV exists by any route. The FDA searched in 2026 and found "no clinical studies or human exposure data" at all.3
KPV penetrates human skin poorly, which limits both the risk and the plausibility of the topical products it was nominated as.3
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend KPV for the 503A bulks list for wound healing and inflammatory conditions, against the FDA's recommendation. The vote is advisory and the FDA has not acted on it.5 3
A targeted PubMed search returns 88 records, many of them incidental mentions of the sequence. None is a trial.

The Most Common Error About This Compound

Reading the July 2026 vote as evidence. The committee recommended KPV for compounding on a nomination that proposed a 0.1 percent topical cream and gel; the FDA's review found no human data, no toxicology, no impurity specifications and a substance it could not consider well characterised.3 A vote for access is not a finding of effect. And the products actually sold, injectable, oral and nasal KPV for gut health, are not the product the committee discussed.

Identity

What Is KPV?

Alpha-melanocyte-stimulating hormone is a 13-residue peptide cut from the same precursor as ACTH. It darkens skin through the melanocortin-1 receptor, and it has been known since the 1990s to suppress inflammation both centrally and in the periphery. Its last three residues, Lys-Pro-Val, turned out to carry most of the anti-inflammatory activity and none of the pigmentary one.4 1

That separation is the whole rationale. A molecule that quiets inflammation without acting on melanocortin receptors would avoid the pigmentation, appetite and sexual side effects of the parent hormone and its analogues. The FDA's summary is that KPV "does not appear to interact with the melanocortin receptors" and that its "molecular targets are unknown."3

How Might It Work?

The best-characterised mechanism is in the gut. A 2008 study in Gastroenterology showed that nanomolar KPV inhibited NF-κB and MAP kinase signalling in human intestinal epithelial and T cells, that it was taken into cells by PepT1, a di- and tripeptide transporter normally confined to the small intestine but induced in the colon during inflammatory bowel disease, and that KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice.2 That PepT1 route is the basis of a decade of nanoparticle and hydrogel formulation work aimed at delivering KPV to an inflamed colon.6

Separately, alpha-MSH and KPV have direct antimicrobial activity against Staphylococcus aureus and Candida albicans in vitro, which is why a cyclised dimer, (CKPV)2, has been studied for fungal infection.7 That is a different molecule from the tripeptide sold as KPV.

Evidence Base

What Do the Animal Studies Show?

A consistent anti-inflammatory signal in models of gut and skin inflammation. In the 1994 work that established the field, KPV injected intraperitoneally reduced interleukin-1-induced inflammation in the mouse ear and retained that activity in animals with a transected spinal cord, indicating a peripheral action.4 The colitis models followed. A 2019 review of melanocortin peptides for cutaneous wound healing lays out the in silico, in vitro and animal work and, in its own words, offers "an unbiased discussion of the pro and contra arguments" for developing them, which is a phrase authors use when the case is not yet made.8

What Human Evidence Exists?

None. This is not a summary; it is the finding of a regulator that looked.

The FDA's July 2026 evaluation states that the nominator "did not provide clinical evidence on the use of KPV in wound healing or inflammatory conditions," that the agency "performed a search of published medical literature and FDA did not identify data, such as clinical studies, on the use of KPV in humans," and, on safety, that it "has not identified, any clinical studies or human exposure data for KPV via any route of administration."3 No trial is registered on ClinicalTrials.gov.9

The related tripeptide KdPT, lysine-D-proline-threonine, derived from interleukin-1β rather than alpha-MSH, was taken into clinical development in Europe for inflammatory skin and bowel disease in the 2000s.1 It is a different molecule and its results do not transfer.

What Was Nominated, and What Is Sold?

	The nomination the committee voted on	The products on the market
Form	0.1 percent cream and gel, topical3	Injectable, oral capsule, nasal spray, and multi-peptide blends3
Use	Wound healing; psoriasis, eczema	Inflammation, inflammatory bowel disease, gut health, nerve damage, stroke, psoriasis
Human data	None	None

The FDA noted that KPV's low skin permeability "could limit the systemic toxicity" of a topical product and "could also limit the potential effectiveness," because it may not reach the living layers of the epidermis.3 The injectable products bypass that limitation and, with it, the one safety argument the topical route had.

Safety

What Is Known?

Nothing from humans. The FDA's adverse event database and its foods complaint system returned no reports, which the agency says "does not imply that the substance is safe or lacks toxicities." It found no nonclinical toxicity studies either: no repeat-dose, genotoxicity, reproductive or carcinogenicity work of any kind.3

What can be said on the compound's behalf is structural. It is three natural amino acids, it is a fragment of a hormone every person makes, and the parent hormone has a long safety record in its own right. That is a reason to expect low toxicity. It is not a measurement of it.

What Is Unknown

Everything that would normally define a safety profile: dose, route, duration, interactions, immunogenicity. The FDA's specific concern was "the lack of human data on drug products containing KPV administered via any route of administration, including lack of information to assess immunogenic safety risks."3 A tripeptide is an unlikely immunogen on its own; aggregated or impure product is a different question, and nobody has asked it.

Regulatory Status

Is It Approved Anywhere?

No. KPV has no marketing authorisation in any jurisdiction, no USP monograph, and is not a component of any approved drug. It is not recognised by the European Medicines Agency or the European or Japanese pharmacopoeias.3

What Happened in July 2026?

In September 2023 the FDA placed KPV in Category 2 of its interim compounding policy, the category for substances that may present significant safety risks, on the basis that it "has not identified any human exposure data on drug products containing KPV administered via any route." As of April 2026 it appears among substances nominated but withdrawn.10

On 23 July 2026 the Pharmacy Compounding Advisory Committee considered KPV free base and acetate for the 503A bulks list. The nomination had been withdrawn by its nominator; the FDA proceeded at its discretion and proposed against inclusion, concluding the substances "are not well-characterized," that the extent of compounding use is unknown, and that there is a "lack of information on their use when administered in humans to make a conclusion on their clinical safety and effectiveness."3

The committee voted 8 to 6, with one abstention, to recommend inclusion for wound healing and inflammatory conditions.5 Advisory committee recommendations are non-binding. As of this page's verification date the FDA has not added KPV or any of the other five recommended peptides to the bulks list, which can only be amended by rulemaking, and no pharmacy in the United States has a lawful basis on which to compound it.

The vote was on a topical cream for wounds and eczema. If the FDA eventually acts on it, that is what would become compoundable. An injectable KPV for gut health would remain exactly where it is now.

Related ONPEPS Coverage

What Would Change This Page

A single human study, of any design, would be the first. The FDA's decision on the July recommendation, whichever way it goes, would change the access position for a topical product. A formulation that actually reaches an inflamed colon in a person, which the nanoparticle literature has been working toward for a decade, would be the thing worth waiting for.6

References

Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55. Open access. pubmed.ncbi.nlm.nih.gov/17934097
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. Open access. pubmed.ncbi.nlm.nih.gov/18061177
US Food and Drug Administration. KPV-related bulk drug substances (KPV (free base) and KPV acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 23 July 2026. Docket FDA-2025-N-6895. Primary source for the nomination, the characterisation, effectiveness and safety findings, and the FDA's recommendation. fda.gov
Macaluso A, McCoy D, Ceriani G, Watanabe T, Biltz J, Catania A, Lipton JM. Antiinflammatory influences of alpha-MSH molecules: central neurogenic and peripheral actions. J Neurosci. 1994;14(4):2377-2382. Open access. pubmed.ncbi.nlm.nih.gov/8158274
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 8 to 6 vote with one abstention on KPV, drawing on contemporaneous reporting by NPR, Reuters and STAT. onpeps.com
Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y, et al. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater. 2022;143:233-252. Paywalled. pubmed.ncbi.nlm.nih.gov/35245681
Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. Open access. pubmed.ncbi.nlm.nih.gov/10670585
Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019;28(3):219-224. Paywalled. pubmed.ncbi.nlm.nih.gov/30661264
ClinicalTrials.gov. Studies listing KPV peptide as an intervention. Registry search returning no studies; checked 16 September 2026. clinicaltrials.gov
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for KPV. Content current as of 22 April 2026. fda.gov

Not Medical Advice

KPV is not approved for human use in any jurisdiction and has never been studied in a human being by any route. Consult a qualified healthcare provider before acting on anything here.

Evidence counts on the library index retrieved 23 July 2026. Literature and regulatory sources verified 16 September 2026. The FDA had not acted on the July 2026 advisory recommendation as of that date. Re-verify against docket FDA-2025-N-6895 before relying on any regulatory statement here.

KPV